Sample of Key Takeaways
The response data provides the average of all responders.
- More data on biosimilar outcomes in a Canadian practice setting are needed. 3.8/5
- Health care providers will be required to offer additional patient interaction time to implement non-medical switches. 4.9/5
- Current polices will allow savings from biosimilar adoption to fund access to new therapies. 2.5/5